

## Thiazolocarboxamide Analogues as NAMPT Inhibitors

Jean-Francois Brazeau<sup>†</sup> and Gerard Rosse<sup>\*,†,‡</sup><sup>†</sup>Structure Guided Chemistry, Dart Neuroscience LLC, 7473 Lusk Boulevard, San Diego, California 92121, United States<sup>‡</sup>Adjunct Associate Professor, Department of Pharmacology and Physiology, College of Medicine, Drexel University, New College Building, 245 North 15th Street, Philadelphia, Pennsylvania 19102, United States

**Title:** Thiazolocarboxamide Analogues as NAMPT Inhibitors

**Patent/Patent Application Number:** WO 2013170118 **Publication date:** November 14, 2013

**Priority Application:** WO 2012-CN75327 **Priority date:** May 11, 2012


**Inventors:** Sweis, R. F.; Curtin, M. L.; Pliushchev, M. A.; Hansen, T. M.; Longenecker, K.

**Assignee Company:** Abbvie Inc., USA


**Disease Area:** Cancer **Biological Target:** NAMPT

**Summary:** The present application claims a series of thiazolocarboxamide analogues, which inhibit the activity of nicotinamide phosphoribosyltransferase (NAMPT). The compounds claimed in this patent could potentially be useful for the development of new cancer therapies.


## Important Compound Classes:




## Key Structures:




Compound 5



Compound 27



Compound 136



Compound 151

**Recent Review Articles:** Galli, M.; Van Gool, F.; Rongvaux, A.; Andris, F.; Leo, O. *Cancer Res.* **2010**, *70*, 8.

**Biological Assay:** Compound efficacy was evaluated using TR-FRET binding assay (in presence of PRPP)

**Pharmacological Data:**

	TR-FRET binding (IC <sub>50</sub> , nM)
Compound 5	0.461
Compound 27	0.632
Compound 136	0.174
Compound 151	0.412

**Synthesis:** 213 compounds were synthesized

## ■ AUTHOR INFORMATION

## Corresponding Author

\*E-mail: grosse@dartneuroscience.com.

## Notes

The authors declare no competing financial interest.

Received: January 31, 2014

Published: February 13, 2014